Publications Database

Blankenship K. et al. (2010)

Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years.

Pediatric Health

4(4), pp. 375-381

Read Abstract (New Window) Read Full (New Window)

Blankenship K. et al. (2011)

Guanfacine, extended, release, two, patients, pervasive, developmental, disorders

Journal of Child and Adolescent Psychopharmacology

21(3), pp. 287-290

Bowers K. , Lin P. , Erickson C. A. (2015)

Pharmacogenomic medicine in autism: Challenges and opportunities.

Pediatric Drugs

April, 17(2), pp. 115-124.

Read Abstract (New Window)

Caldwell R. L. et al. (2012)

The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.

Research in Autism Spectrum Disorders

August, 22(4), pp. 277-283.

Read Abstract (New Window) Read Full (New Window)

Early M. C. et al. (2012)

Case report: 16-year-old male with autistic disorder with preoccupation with female feet.

Journal of Autism and Developmental Disorders

May, 42(6), pp. 1133-1137.

Read Abstract (New Window)

Erickson C. A. et al. (2011)

A prospective open-label study of aripiprazole in fragile X syndrome.

Psychopharmacology (Berl)

July, 216(1), pp. 85-90.

Read Abstract (New Window)

Erickson C. A. et al. (2011)

A prospective open-label study of aripiprazole in fragile X syndrome.

Psychopharmacology (Berl)

July, 216(1), pp. 85-89.

Read Abstract (New Window)

Erickson C. A. et al. (2007)

A retrospective study of memantine in children and adolescents with pervasive developmental disorders.

Psychopharmacology (Berl)

191(1), pp. 141-147

Read Abstract (New Window)

Erickson C. A. et al. (2011)

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder

Journal of Child and Adolescent Psychopharmacology

Read Abstract (New Window)

Erickson C. A. et al. (2010)

Aripiprazole in autism spectrum disorders and fragile X syndrome.

Neurotherapeutics

7(3), pp. 258-263

Read Abstract (New Window)

Erickson C. A. , Mullett J. , McDougle C. J. (2010)

Brief report: acamprosate in fragile X syndrome.

Journal of Autism and Developmental Disorders

40(11), pp. 1412-1416.

Read Abstract (New Window)

Erickson C. A. et al. (2014)

Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.

Journal of Autism and Developmental Disorders

April, 44(4), pp. 981-987.

Read Abstract (New Window)

Erickson C. A. et al. (2005)

Gastrointestinal factors in autistic disorder: a critical review.

Journal of Autism and Developmental Disorders

35(6), pp. 713-727

Read Abstract (New Window)

Erickson C. A. et al. (2013)

Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

Psychopharmacology (Berl)

July, 228(1), pp. 75-78.

Read Abstract (New Window)

Erickson C. A. , Chambers J. (2006)

Memantine for disruptive behavior in autistic disorder.

Journal of Clinical Psychiatry

67(6), pp. 1000

Erickson C. A. , Mullett J. E. , McDougle C. J. (2009)

Open-label memantine in fragile X syndrome.

Journal of Autism and Developmental Disorders

39(12), pp. 1629-1635.

Read Abstract (New Window)

Erickson C. A. et al. (2014)

STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study.

Journal of Autism and Developmental Disorders

44(4), pp. 958-964.

Read Abstract (New Window)

Fitzpatrick S. E. et al. (2016)

Aggression in autism spectrum disorder: presentation and treatment options.

Neuropsychiatric Disease and Treatment

2016(12), pp. 1525-1538

Read Abstract (New Window) Read Full (New Window)

Kowalski J. et al. (2011)

Paliperidone palmitate in a child with autistic disorder.

Journal of Child and Adolescent Psychopharmacology

October, 21(5), pp. 491-493

McDougle C. J. et al. (2008)

Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.

Journal of Clinical Psychiatry

69 pp.15-20

Read Abstract (New Window)